Maximum quantity allowed is 999
请选择数量
CAS RN: 129-06-6 | 產品號碼: W0005
Warfarin Sodium (contains Isopropyl Alcohol)
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | W0005 |
| 純度/分析方法 | >98.0%(HPLC) |
| 分子式 / 分子量 | C__1__9H__1__5NaO__4 = 330.31 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive |
| CAS RN | 129-06-6 |
| 相關CAS RN | 81-81-2 |
| Reaxys-RN | 5469050 |
| PubChem Substance ID | 87560363 |
| Merck Index(14) | 10038 |
| MDL編號 | MFCD00083223 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 91.0 % |
| 2-Propanol | 7.0 to 9.0 % |
性質
| 溶解性（微溶於） | Ether, Chloroform |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H300 : Fatal if swallowed. H360 : May damage fertility or the unborn child. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H373 : May cause damage to organs through prolonged or repeated exposure. H412 : Harmful to aquatic life with long lasting effects. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | GN4725000 |
運輸資料
| UN編號 | UN1544 |
| 類別 | 6.1 |
| 包裝類別 | II |
| HS編碼* | 2932.20-000 |
Application
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin
Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.
References
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
Application
Reviews of Pharmacology of Warfarin
References
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
- Systematic overview of warfarin and its drug and food interactions
- Pharmacogenetics of warfarin elimination and its clinical implications
- Pharmacogenetics of warfarin: current status and future challenges
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
考研文獻
文章/手冊
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。